Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda

 
• By Sten Stovall

The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.

Digestive_System
Their alliance will first focus on gastrointestinal targets • Source: Shutterstock

More from Business

More from Scrip